Organization (Industry)
ASCENDIS PHARMA A/S
ClinicalTrials.gov lists ASCENDIS PHARMA A/S as lead sponsor of 30 trials, counting the companies grouped under it. ASCENDIS PHARMA A/S itself has 19 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers ASCENDIS PHARMA A/S and 4 companies grouped under it: 30 lead-sponsored trials (15 its own, 15 in the grouped companies) and 3 legal-entity registrations (3 its own, 0 in the grouped companies).
Companies grouped under this page (4)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Ascendis Pharma Endocrinology Division A/S | 7 | 0 |
| Ascendis Pharma Bone Diseases A/S | 3 | 0 |
| Ascendis Pharma Growth Disorders A/S | 3 | 0 |
| Ascendis Pharma Oncology Division A/S | 2 | 0 |
Disease areas (11)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dwarfism | 9 |
| Achondroplasia | 4 |
| Dwarfism, Pituitary | 4 |
| Hypoparathyroidism | 4 |
| Failure to Thrive | 2 |
Showing 5 of 11 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2020 | 1 |
| 2019 | 3 |
| 2017 | 1 |
| 2015 | 1 |
| 2013 | 1 |
| 2010 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (19)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Palopegteriparatide | Hypoparathyroidism | Phase 3 | 4 |
| TransCon hGH | Failure to Thrive | Phase 3 | 1 |
| TransCon hGH | Dwarfism, Pituitary | Phase 3 | 1 |
| TransCon hGH | Dwarfism | Phase 3 | 1 |
| Navepegritide | Achondroplasia | Phase 2 | 3 |
Showing 5 of 19 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Palopegteriparatide | 4 |
| Somatropin | 3 |
| PEMBROLIZUMAB | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=5) | 60% on time (n=5) |
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of clinical endocrinology and metabolism | 4 |
| EClinicalMedicine | 1 |
| Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society | 1 |
| Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 49 | 23 | 2025-08-26 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 812,388,341 | -257,247,509 | 342,517,983 |
| 2024 | 393,457,099 | -409,084,327 | 332,176,248 |
| 2023 | 288,621,016 | -520,983,669 | 447,407,050 |
| 2022 | 53,809,979 | -613,234,401 | 399,178,483 |
| 2021 | 9,196,552 | -453,533,802 | 349,827,246 |
| 2020 | 7,929,050 | -477,767,190 | 297,529,260 |
| 2019 | 14,998,575 | -244,480,700 | 214,881,643 |
| 2018 | 12,436,745 | -152,914,020 | 164,884,138 |
| 2017 | 1,723,920 | -139,600,353 | 112,211,430 |
| 2016 | 5,093,329 | -75,753,053 | 73,007,343 |
Showing 10 of 11 fiscal years.
Financing and grant events (172)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-14 | Other financing | not disclosed | Sec extracted |
| 2026-06-29 | Other financing | 21,552,508 | Sec extracted |
| 2026-06-17 | Other financing | 187,500,000 | Sec extracted |
| 2026-06-09 | Other financing | not disclosed | Sec extracted |
| 2026-05-12 | Other financing | not disclosed | Sec extracted |
Showing 5 of 172 events.
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Ascendis Pharma A/S | Hellerup, DK | EMA, FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (274)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026 Q4 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026 Q4 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-07-14 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-29 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-17 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 274 events.
Biomarker capability evidence (38)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| GH1 | Trial sponsor | Named in trial inclusion criteria |
| GH1 | Trial sponsor | Named in trial inclusion criteria |
| IGF1 | Trial sponsor | Named in trial inclusion criteria |
| IGF1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 38 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.